HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

472.038

-10.181-2.11%

Number of Gainers:4

Number of Losers:28

Number of Flat:2

PE:- -

High:489.517

Open:482.071

Low:460.033

Close:482.219

Loading ...

the Phase Iii Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

THOMSON REUTERS

HBM Holdings' 2024 Profit Shrinks

MT Newswires Live

Ocumension Therapeutics' 2024 Loss Narrows

MT Newswires Live

BUZZ-CStone Pharmaceuticals hits 5-week low on discounted share sale

CStone Pharmaceuticals to Raise HK$232 Million from Share Placement

MT Newswires Live

BRIEF-Cstone Pharmaceuticals To Place Aggregate Of 80 Million Placing Shares

CStone Pharmaceuticals - to Place Aggregate of 80 Mln Placing Shares at HK$2.933 per Share

THOMSON REUTERS

Peijia Medical Collaborates With Dsm-Firmenich to Create Groundbreaking Innovative Medical Device Products

THOMSON REUTERS

Ascletis Pharma Reports Positive Interim Results for Obesity Treatment; Shares Up 6%

MT Newswires Live

Immunotech Biopharm's 2024 Loss Narrows

MT Newswires Live

Immunotech Biopharm FY Pretax Profit RMB -186.4 Million

THOMSON REUTERS

Ocumension Therapeutics FY Net Income RMB -268.3 Million

THOMSON REUTERS

SinoMab BioScience FY Net Income RMB -185.1 Million

THOMSON REUTERS

Akeso Swings to Loss in 2024

MT Newswires Live

BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Ascletis Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30, a Potentially First-in-Class Subcutaneous Injection Small Molecule Glp-1R Agonist

THOMSON REUTERS

Ascletis Pharma Inc - Asc30 Sq Injection Shows 36-Day Half-Life in Obesity Patients

THOMSON REUTERS

Ascletis Pharma: Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30

THOMSON REUTERS

Harbour Biomed Reports Full Year 2024 Financial Results

THOMSON REUTERS

Press Release: Harbour BioMed Reports Full Year 2024 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":472.03796,"timestamp":1743667695054,"preClose":482.21906,"halted":0,"volume":193595650,"delay":0,"changeRate":-0.021113,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-10.181091,"latestTime":"04-03 16:00:00","open":482.07123,"high":489.5174,"low":460.0333,"amount":3523389693,"amplitude":0.061143,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743989400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1743643800000,1743652800000],[1743656400000,1743667200000]],"pbRate":3.839353,"peRate":-23.027281,"turnoverRate":0.007371,"increases":4,"decrements":26,"flats":3,"marketCap":268451106368,"floatMarketCap":251733018784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":489.5174,"amplitude":0.061143,"preClose":482.21906,"low":460.0333,"pbRate":"3.839353","latestPrice":472.03796,"volume":193595650,"delay":0,"open":482.07123,"prevYearClose":331.1933,"prevWeekClose":459.856,"prevMonthClose":455.082,"prevQuarterClose":455.082,"fiveDayClose":439.4,"twentyDayClose":430.463,"sixtyDayClose":323.945,"secType":"PLATE","market":"HK","turnoverRate":0.007371,"peRate":-23.027281,"marketCap":268451106368,"floatMarketCap":251733018784,"timestamp":1743667695054,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":4,"down":28,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525771311","title":"the Phase Iii Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2525771311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525771311?lang=en_us&edition=fundamental","pubTime":"2025-04-05 22:17","pubTimestamp":1743862632,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250405:nTUA7MNXR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","02162","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2524251465","title":"HBM Holdings' 2024 Profit Shrinks","url":"https://stock-news.laohu8.com/highlight/detail?id=2524251465","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524251465?lang=en_us&edition=fundamental","pubTime":"2025-04-02 18:48","pubTimestamp":1743590934,"startTime":"0","endTime":"0","summary":"HBM's  profit plunged to $2.7 million in 2024 from $22.8 million in 2023.The drug company logged zero earnings per share during the year compared with $0.03 in the previous year, according to a Monday filing with the Hong Kong bourse.Revenue shrank to $38.1 million from $89.5 million a year earlier.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2524463703","title":"Ocumension Therapeutics' 2024 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2524463703","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524463703?lang=en_us&edition=fundamental","pubTime":"2025-04-02 18:41","pubTimestamp":1743590489,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics'  loss narrowed to 268.3 million yuan in 2024 from 379.8 million yuan in 2023.Loss per share at the drug manufacturer narrowed to 0.39 yuan from 0.59 yuan in the previous year, according to a Monday filing with the Hong Kong bourse.Revenue grew 69% to 417.3 million yuan from 246.4 million yuan a year earlier.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK4139","BK1191","01477","LENZ"],"gpt_icon":0},{"id":"2524108018","title":"BUZZ-CStone Pharmaceuticals hits 5-week low on discounted share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2524108018","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524108018?lang=en_us&edition=fundamental","pubTime":"2025-04-02 09:54","pubTimestamp":1743558885,"startTime":"0","endTime":"0","summary":"BUZZ-CStone Pharmaceuticals hits 5-week low on discounted share sale** CStone Pharmaceuticals 2616.HK slides 13% to HK$3, lowest since February 25** Stock set for biggest one-day pct decline since March 7, 2024; top pct loser on Hong Kong bourse** Chinese biopharma developer plans to sell 80 mln new shares to third party investors to raise HK$234.6 mln  for R&D and general corporate purposes** Says shares will be issued at HK$2.933, representing ~15% discount to Tuesday's close of HK$3.45** Stock gains 30.4% YTD    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nL2N3QG01X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2524617235","title":"CStone Pharmaceuticals to Raise HK$232 Million from Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2524617235","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524617235?lang=en_us&edition=fundamental","pubTime":"2025-04-02 09:10","pubTimestamp":1743556211,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  plans to issue up to 80 million shares to at least six investors under a placement deal at HK$2.933 apiece, according to a Wednesday filing with the Hong Kong bourse.The shares comprise 5.86% of the entire share capital of the drug company following completion.Net proceeds, estimated at HK$232.3 million, will be used for the development of cancer drugs and for other general corporate purposes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2524179253","title":"BRIEF-Cstone Pharmaceuticals To Place Aggregate Of 80 Million Placing Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2524179253","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524179253?lang=en_us&edition=fundamental","pubTime":"2025-04-02 08:43","pubTimestamp":1743554613,"startTime":"0","endTime":"0","summary":"BRIEF-Cstone Pharmaceuticals To Place Aggregate Of 80 Million Placing SharesApril 2 (Reuters) - CStone Pharmaceuticals 2616.HK:TO PLACE AGGREGATE OF 80 MILLION PLACING SHARES AT HK$2.933 PER SHAREFurther company coverage: 2616.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2524175182","title":"CStone Pharmaceuticals - to Place Aggregate of 80 Mln Placing Shares at HK$2.933 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2524175182","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524175182?lang=en_us&edition=fundamental","pubTime":"2025-04-02 08:01","pubTimestamp":1743552093,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF0ZA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2524904761","title":"Peijia Medical Collaborates With Dsm-Firmenich to Create Groundbreaking Innovative Medical Device Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2524904761","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524904761?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:00","pubTimestamp":1743508808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA5NTN9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","09996","BK1100"],"gpt_icon":0},{"id":"2524915612","title":"Ascletis Pharma Reports Positive Interim Results for Obesity Treatment; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524915612","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524915612?lang=en_us&edition=fundamental","pubTime":"2025-04-01 15:10","pubTimestamp":1743491410,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  posted promising Phase Ib trial results in the U.S. for ASC30, a potential first-in-class GLP-1 receptor agonist for treating obesity, according to a Monday filing with the Hong Kong bourse.A single subcutaneous injection of ASC30 showed a 36-day half-life, supporting once-monthly dosing. The oral tablet form of ASC30 also demonstrated \"6.3% weight loss in patients with obesity after a four-week treatment.\"Ascletis holds global patent protection until 2044 for ASC30.The pharmaceutical shares were up by 5.8%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1515","BK1574","01672"],"gpt_icon":0},{"id":"2524035133","title":"Immunotech Biopharm's 2024 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2524035133","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524035133?lang=en_us&edition=fundamental","pubTime":"2025-04-01 11:31","pubTimestamp":1743478271,"startTime":"0","endTime":"0","summary":"Immunotech Biopharm's  loss attributable to owners in 2024 narrowed year on year to 186.9 million yuan or 0.36 per share from 334.8 million yuan or 0.65 yuan per share, according to a Hong Kong Stock Exchange disclosure on Monday.The biopharmaceutical company's other income surged 220% to 33.8 million yuan from 10.5 million yuan in the previous year.No dividend was recommended for the period.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2523923777","title":"Immunotech Biopharm FY Pretax Profit RMB -186.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523923777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523923777?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:45","pubTimestamp":1743432305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX34538D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2523941247","title":"Ocumension Therapeutics FY Net Income RMB -268.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941247?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:00","pubTimestamp":1743426027,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX18B674:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2523103119","title":"SinoMab BioScience FY Net Income RMB -185.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523103119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523103119?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:18","pubTimestamp":1743419932,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLXA4E8B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","03681","BK1574"],"gpt_icon":0},{"id":"2523164917","title":"Akeso Swings to Loss in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2523164917","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523164917?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:07","pubTimestamp":1743419274,"startTime":"0","endTime":"0","summary":"Akeso  swung to an attributable loss of 514.5 million yuan in 2024 from a profit of 2.03 billion yuan in 2023, according to a Sunday filing with the Hong Kong bourse.The biopharmaceuticals producer swung to a loss per share of 0.60 yuan from earnings per share of 2.42 yuan in the previous year.Revenue declined 53% to 2.12 billion yuan from 4.53 billion yuan a year earlier.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BPRC5H50.USD","LU0348783233.USD","IE00B5MMRT66.SGD","LU1720050803.USD","BK1574","LU2488822045.USD","LU1794554557.SGD","LU0417516571.SGD","IE00B543WZ88.USD","09926","BK1161","LU0348784397.USD"],"gpt_icon":0},{"id":"2523491203","title":"BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2523491203","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523491203?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:02","pubTimestamp":1743418956,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R AgonistMarch 31 (Reuters) - Ascleti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA4T6HRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","01672","BK1574"],"gpt_icon":0},{"id":"2523912791","title":"Ascletis Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30, a Potentially First-in-Class Subcutaneous Injection Small Molecule Glp-1R Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912791?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA4T6HRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","01672","BK1161"],"gpt_icon":0},{"id":"2523912730","title":"Ascletis Pharma Inc - Asc30 Sq Injection Shows 36-Day Half-Life in Obesity Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912730?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA4T6HRZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","BK1161","01672"],"gpt_icon":0},{"id":"2523912676","title":"Ascletis Pharma:  Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912676?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:55","pubTimestamp":1743418510,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0UL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2523879919","title":"Harbour Biomed Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523879919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523879919?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743416021,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA5CH63Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2523191987","title":"Press Release: Harbour BioMed Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523191987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523191987?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743415980,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025. CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed,  commented: \"The year 2024 was a pivotal period for Harbour BioMed, marked by significant progress in research and development, strategic business expansion, and operational excellence. Despite a challenging macroeconomic environment, the Company demonstrated remarkable resilience, navigating inflationary pressures, global supply chain disruptions, and geopolitical uncertainties while remaining focused on its long-term growth objectives.Compared to 2023, the company's revenue sustainability has continued to improve. Annual recurring revenue in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4555","BK4585","BK4588","02142","BK4099","03160","BK1161","BK1574","BK4232","SD","TSLP","BK4604","BK4022","TM","BK4213","R"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69}]}}